DRIO — DarioHealth Corp.

DarioHealth Corp. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $5.2 million, reflecting sequential growth.
• Full-Year Revenue: $22.4 million, down from $27.0 million in 2024 due to the non-renewal of a legacy client contract.
• Annualized Recurring Revenue (ARR): $12.9 million in contracted and late-stage opportunities expected to contribute in 2026 and 2027.
• Gross Margin: Increased to 57% in 2025 from 49% in 2024, primarily due to reduced technology amortization expenses.
• Operating Expenses: Declined by 31% to $49.3 million in 2025, with Q4 operating expenses down 28% year-over-year.
• Cash Position: Ended 2025 with $26.0 million in cash and short-term deposits, with net cash used in operations reduced by 33% from 2024.

2. Strategic Updates and Business Highlights

• New Business Wins: Signed 85 new agreements in 2025, significantly exceeding the target of four, with contract sizes 2 to 10 times larger than historical averages.
• Commercial Pipeline: Expanded to $122 million, with strong demand for multi-condition digital health solutions.
• Partnerships: Key partnerships established with major health plans like Florida Blue and UnitedHealthcare, enhancing access to over 160 million covered lives.
• AI Integration: Leveraging proprietary data and AI capabilities through DarioIQ to enhance platform effectiveness and competitive positioning.

3. Forward Guidance and Outlook

• Revenue Growth: Expected to continue in 2026, with the second half anticipated to show the strongest acceleration.
• Operating Loss Reduction: Targeting a 30% reduction in non-GAAP operating loss in 2026, with a goal of reaching cash flow breakeven by mid-2027.
• Market Position: Positioned to capitalize on the shift towards integrated digital health platforms that address multiple chronic conditions.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The significant drop in annual revenue was attributed to the non-renewal of a legacy client contract, which is a one-time issue but highlights dependency on key clients.
• Breakeven Timeline: The timeline for achieving cash flow breakeven has been extended, with management indicating that growth will primarily drive this improvement rather than further cost reductions.
• Implementation Challenges: Transitioning to a one-to-many distribution model may require operational adjustments and could present challenges in scaling effectively.

5. Notable Q&A Insights

• Revenue Growth Cadence: Management expressed confidence in achieving revenue growth in 2026, with an expectation of acceleration in the latter half of the year.
• Capture Rate and Partnerships: Discussion on how being a preferred partner within large health plans (e.g., HCSC) facilitates easier access to business, with self-insured employers having the flexibility to choose from in-network options.
• Pipeline Definitions: Clarification that the commercial pipeline now includes opportunities for both 2026 and 2027, reflecting a broader view of potential revenue streams.

Overall, DarioHealth Corp. demonstrated strong strategic positioning and growth potential despite facing some challenges related to past client dependencies and operational adjustments. The company is optimistic about its future trajectory, driven by a robust pipeline and expanding partnerships.